oleandrin
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT01562301)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
ATP1A1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)O[C@H]1C[C@]2(O)[C@@H]3CC[C@@H]4C[C@@H](O[C@H]5C[C@H](O)[C@@H](O)[C@H](C)O5)CC[C@]4(C)[C@H]3CC[C@]2(C)[C@H]1C1=CC(=O)OC1- Mol. weight
- 562.7 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4285883 ↗
- ChEMBLCHEMBL1075789 ↗
Also known as
- anvirzel
- anvirzel
- anvirzel
- corrigen
- foliandrin
- folinerin
- neriostene
- oleandrin
- oleandrin
- oleandrin
- oleandrin
- oleandrin
- oleandrina
- oleandrina
- oleandrine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01562301 | Phase 1 | Jun 1, 2014 | National Cancer Institute (NCI), Nerium Biotechnology, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2014 |
| Nerium Biotechnology | For profit | 1 | 0 | 1 | 2014 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2014 |
3 organizations
Page 1 / 1